Acorda Therapeutics (NASDAQ:ACOR):
INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Acorda Therapeutics, Inc. (ACOR).
The company is trading up by 1.76% since yesterday’s close of 17.
Acorda Therapeutics, Inc., launched on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS..
The company’s P/E ratio is N/A and the market cap of the company is 808.73M. As of the last earnings report the EPS was $-1.21 with 46.75M shares now outstanding.
Investors are a little more bullish on shares of Acorda Therapeutics of late if you take into consideration the downtick in short interest. The firm recorded a fall in short interest of -12.70% as of October 13, 2017 from the last reporting period. Short interest decreased from 6,295,526 to 5,496,213 over that timeframe. The days to cover decreased to 7.0 and the short interest percentage is 0.12% as of October 13.
A few brokerage firms have weighed in on Acorda Therapeutics. Oppenheimer Holdings released research on ACOR by announcing an initial rating of “Market Perform”. Equity analyst CIBC released guidance on ACOR with an initial rating of “Market Perform”.
On November 8, 2017 HC Wainwright released a research note on ACOR giving it an initial rating of “Buy”. Equity analyst Jefferies Group LLC raised the price target on November 1 boosting the projection from $22.00 to $25.00 and issued a “Hold” recommendation.
On October 31 analysts at J P Morgan Chase & Co updated coverage of ACOR and giving a rating of “Hold” and price target of $24.00. On October 31 Cantor Fitzgerald kept the stock rating at “Hold” targeting a price of $18.00.